ESMO Asia 2016 Congress: ESMO Colloquia

The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. 

The Colloquia are organised by ESMO and supported by the industry and are unique collaborations, making them the perfect complement to the scientific and educational programme of the Congress.

Friday, 16 December

ESMO Colloquium: Bone Integrity in Cancer Patients

ESMO Asia 2016 Colloquia Bone Integrity in Cancer Patients square

Room: Hall 405, 12:45 - 14:15
The ESMO Asia Colloquium on Bone integrity in cancer patients is provided by ESMO and supported by Amgen.
View the ESMO Colloquium details

Learning Objectives

  1. To learn about bone metabolism and its physiologic regulation and its modification by malignant disease
  2. To learn about morbidity and incidence of skeletal-related events in malignancy
  3. To learn about pharmacologic intervention options to influence bone metabolism in malignancy
  4. To learn about modalities to control and prevent the development of skeletal-related events and the efficacy of available therapies in various malignancies
  5. To learn about differences between treatment options
  6. To learn about the management of toxicities

Sunday, 18 December

ESMO Colloquium: New Perspectives in the Management of Prostate Cancer

ESMO Asia 2016 Colloquia New Perspectives in the Management of Prostate Cancer square

Room: Hall 404, 12:45 - 14:15
The ESMO Asia Colloquium on New Perspectives in the Management of Prostate Cancer is provided by ESMO and supported by Astellas.
View the ESMO Colloquium details

Learning Objectives

  1. To understand the role of ARV7 as predictive and prognostic biomarker in CRPC,
  2. To analyse the rationale and the outcome of combined chemo and hormone therapy in non-personalised phase III trials
  3. To update on the progress made in personalized strategies in prostate cancer
  4. To understand the role of genomic aberrations in DNA repair as an emerging target in patients with mCRPC